11:17 Thu 15 Aug 2019
Shield Therapeutics - Director/PDMR Shareholding
("Shield" or the "Company")
Director / PDMR Shareholding
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 |
Details of the person discharging managerial responsibilities/person closely associated
|
|
a) |
|
|
2 |
Reason for the notification
|
|
a) |
Position/status
|
Chairman |
b) |
Initial notification/ Amendment
|
Initial Notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a) |
|
|
b) |
LEI
|
213800G74QWY15FC3W71 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 1.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 |
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares |
c) |
Price(s) and volume(s)
|
Volumes: 75,000
|
d) |
Aggregated information
-Aggregated volume
-Price
|
75,000
|
e) |
Date of the transaction
|
|
f) |
Place of the transaction
|
|
For further information please contact:
|
|
|
+44 (0)20 7186 8500 |
|
|
|
|
Nominated Adviser and Joint Broker |
|
|
|
|
+44 (0)20 7418 8900 |
|
|
Joint Broker |
|
finnCap Ltd |
+44 (0)20 7220 0500 |
|
|
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
|
+44 (0)7980 541 893 / +44 (0)7584 391 303 |
About
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®/Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru®/Accrufer® is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the
Forward-Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Feraccru®/Accrufer®. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE